Literature and evidence database
Find the source, the model and the boundary.
Search source records connected to the product-family knowledge base. Filter by category, product, publication year, research type, study model and editorial evidence tier.
Product evidence maps
A focused source set for each product.
Search and filter
Evidence records
Narrow the records by product, year or study model. Open each source to check its results and limitations.
FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration. Content current through May 31, 2026.
TRIUMPH-1 sponsor-reported topline results
Eli Lilly and Company. May 21, 2026. Sponsor news release; not a full peer-reviewed report.
TRIUMPH-2 and TRIUMPH-3 sponsor-reported topline results
Eli Lilly and Company. July 23, 2026. Sponsor news release; detailed publication pending.
ZEPBOUND (tirzepatide) prescribing information
U.S. FDA. Revised 2026. NDA 217806.
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. N Engl J Med. 2022;387:205–216. PMID 35658024.
A Study of Retatrutide in Participants Who Have Obesity or Overweight
ClinicalTrials.gov record NCT04881760.
TRIUMPH-1 ClinicalTrials.gov record
Protocol and current study-status record.
Google guidance on people-first content and substantive date changes
Official Google Search Central guidance cited for the editorial-update statement.
Editorial methodology
How records are classified
Records are deduplicated by source URL and linked to every relevant product family. Study type and model are inferred from the citation and editorial evidence label, then reviewed during content QA.
Read the full editorial, AI-assistance and correction policy →
Labels and databases supporting regulatory status, formulation or chemical identity.
Controlled trials, systematic reviews and other clinical records with population-specific interpretation.
Animal, cell, analytical and mechanistic records that cannot establish human outcomes.
Narrative reviews, registries and sponsor reports kept visibly distinct from peer-reviewed outcomes.
Use the records